SCHEMBL2652813

SCHEMBL2652813

COC(=O)c1cc(Oc2ccc(Br)cc2)cc(OC(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.44
LMNA P02545 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
USP2 O75604 1/20 0.42
ULK1 O75385 1/20 0.41
KCNH2 Q12809 1/20 0.41
KMT2A Q03164 3/20 0.41
ACACB O00763 2/20 0.40
ACACA Q13085 2/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PARP10 Q53GL7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10895053 0.87 USP2 (0.53) LMNARAB9ANFKB1NFKB2RELA
SCHEMBL9072522 0.86 USP2 (0.48) GCKSMN1; SMN2USP2KCNH2KMT2A
SCHEMBL3601411 0.86 KMT2A (0.59) GCKUSP2KCNH2KMT2AMEN1
SCHEMBL1261462 0.86 GCK (0.57) GCKLMNARAB9ANPC1SMN1; SMN2
SCHEMBL9072524 0.86 KMT2A (0.54) GCKLMNARAB9ANPC1NFKB1
SCHEMBL2657122 0.84 LMNA (0.51) LMNARAB9ANPC1NFKB1NFKB2
SCHEMBL2657014 0.84 MCL1 (0.51) RAB9ASMN1; SMN2USP2MAPTNPSR1
SCHEMBL3599003 0.84 ALDH1A3 (0.54) GCKUSP2KCNH2KMT2AACACB
SCHEMBL3593389 0.84 HPGD (0.58) GCKLMNARAB9ANPC1SMN1; SMN2
SCHEMBL3599562 0.84 GCK (0.42) GCKUSP2KCNH2KMT2AACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 US disclosed
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 US disclosed
US-10005805-B2 2018-06-26 US disclosed
US-10005805-B2 2018-06-26 US disclosed
US-10005805-B2 2018-06-26 US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 US disclosed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 US disclosed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 US disclosed
EP-2185570-A2 NOVEL ACTIVATORS OF GLUCOKINASE Metabasis Therapeutics, Inc. (US) 2010-05-19 EP disclosed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 WO disclosed
US-20080312207-A1 Compounds SYNGENTA CROP PROTECTION AG (CH) 2008-12-18 US disclosed
US-20080312207-A1 Compounds SYNGENTA CROP PROTECTION AG (CH) 2008-12-18 US disclosed
US-20080312207-A1 Compounds SYNGENTA CROP PROTECTION AG (CH) 2008-12-18 US disclosed
EP-1718625-A1 COMPOUNDS AstraZeneca AB (SE) 2006-11-08 EP disclosed
WO-2005080360-A1 COMPOUNDS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed
WO-2005080360-A1 COMPOUNDS ASTRAZENECA AB (SE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005805-B2 GCKR, GCK, HK1 GCK 2/4885LMNA 3338/4885RAB9A 2395/4885
US-20080312207-A1 Compounds GRK4, PTGER4, GRK5 GCK 111/4885LMNA 2105/4885RAB9A 3476/4885
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885LMNA 3764/4885RAB9A 2391/4885
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885LMNA 3764/4885RAB9A 2391/4885
US-10174062-B2 Activators of glucokinase GCKR, GCK, HK1 GCK 2/4885LMNA 3697/4885RAB9A 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.